Ultragenyx Pharmaceutical, Inc. (RARE)
15.43
-0.14
(-0.90%)
USD |
NASDAQ |
Nov 06, 16:00
15.42
-0.01
(-0.06%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Free Cash Flow : -446.77M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -446.77M |
| June 30, 2026 | -494.47M |
| March 31, 2026 | -507.20M |
| December 31, 2025 | -487.00M |
| September 30, 2025 | -466.39M |
| June 30, 2025 | -442.30M |
| March 31, 2025 | -413.04M |
| December 31, 2024 | -434.18M |
| September 30, 2024 | -439.53M |
| June 30, 2024 | -492.48M |
| March 31, 2024 | -543.61M |
| December 31, 2023 | -521.57M |
| September 30, 2023 | -553.38M |
| June 30, 2023 | -553.20M |
| March 31, 2023 | -528.78M |
| December 31, 2022 | -526.59M |
| September 30, 2022 | -479.67M |
| June 30, 2022 | -438.49M |
| March 31, 2022 | -415.73M |
| December 31, 2021 | -411.79M |
| September 30, 2021 | -423.52M |
| June 30, 2021 | -411.33M |
| March 31, 2021 | -242.64M |
| December 31, 2020 | -176.12M |
| September 30, 2020 | -177.54M |
| Date | Value |
|---|---|
| June 30, 2020 | -203.06M |
| March 31, 2020 | -380.63M |
| December 31, 2019 | -370.22M |
| September 30, 2019 | -343.72M |
| June 30, 2019 | -320.37M |
| March 31, 2019 | -303.52M |
| December 31, 2018 | -294.64M |
| September 30, 2018 | -320.32M |
| June 30, 2018 | -313.16M |
| March 31, 2018 | -284.90M |
| December 31, 2017 | -256.64M |
| September 30, 2017 | -222.26M |
| June 30, 2017 | -190.98M |
| March 31, 2017 | -186.48M |
| December 31, 2016 | -171.16M |
| September 30, 2016 | -165.18M |
| June 30, 2016 | -166.02M |
| March 31, 2016 | -139.19M |
| December 31, 2015 | -110.93M |
| September 30, 2015 | -83.76M |
| June 30, 2015 | -62.65M |
| March 31, 2015 | -56.00M |
| December 31, 2014 | -46.78M |
| September 30, 2014 | -41.49M |
| June 30, 2014 | -36.97M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Ionis Pharmaceuticals, Inc. | -567.50M |
| AbbVie, Inc. | 18.87B |
| Krystal Biotech, Inc. | 310.08M |
| BridgeBio Pharma, Inc. | -369.80M |
| Alnylam Pharmaceuticals, Inc. | 752.13M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -43.00M |
| Cash from Investing (Quarterly) | 58.00M |
| Cash from Financing (Quarterly) | 10.00M |
| Free Cash Flow Per Share (Quarterly) | -0.4407 |
| Free Cash Flow to Equity (Quarterly) | -29.00M |
| Free Cash Flow to Firm (Quarterly) | -26.42M |
| Free Cash Flow Yield | -28.63% |